Do analysts prefer ACB or HRTX?

Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 452.49%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Heron Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ACB or HRTX?

In the previous week, Aurora Cannabis had 11 more articles in the media than Heron Therapeutics. MarketBeat recorded 15 mentions for Aurora Cannabis and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat Aurora Cannabis' score of 0.16 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EYPT or HRTX?

In the previous week, Heron Therapeutics had 2 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 4 mentions for Heron Therapeutics and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.91 beat Heron Therapeutics' score of 0.69 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRTX or PALI?

In the previous week, Palisade Bio had 6 more articles in the media than Heron Therapeutics. MarketBeat recorded 10 mentions for Palisade Bio and 4 mentions for Heron Therapeutics. Palisade Bio's average media sentiment score of 0.82 beat Heron Therapeutics' score of 0.69 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or HRTX?

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 9 mentions for Vanda Pharmaceuticals and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat Vanda Pharmaceuticals' score of 0.48 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRTX or BIOA?

In the previous week, BioAge Labs had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 9 mentions for BioAge Labs and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat BioAge Labs' score of 0.68 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Heron Therapeutics (HRTX) Competitors

$0.36 -0.03 (-7.32%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.36 0.00 (0.00%)

As of 06:30 AM Eastern

Compare

HRTX vs. ACB, EYPT, PALI, VNDA, and BIOA

Should you buy Heron Therapeutics stock or one of its competitors? Heron Therapeutics's main competitors and comparable companies include Aurora Cannabis (ACB), Eyepoint Pharmaceuticals (EYPT), Palisade Bio (PALI), Vanda Pharmaceuticals (VNDA), and BioAge Labs (BIOA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heron Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 452.49%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heron Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$314.07M	0.87	-$88.13M	-$1.41	N/A
Heron Therapeutics	$154.90M	0.44	-$20.19M	-$0.19	N/A

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Heron Therapeutics has a net margin of -22.52% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

In the previous week, Aurora Cannabis had 11 more articles in the media than Heron Therapeutics. MarketBeat recorded 15 mentions for Aurora Cannabis and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat Aurora Cannabis' score of 0.16 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurora Cannabis has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Summary

Heron Therapeutics beats Aurora Cannabis on 9 of the 14 factors compared between the two stocks.

How does Heron Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Heron Therapeutics has a net margin of -22.52% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

In the previous week, Heron Therapeutics had 2 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 4 mentions for Heron Therapeutics and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.91 beat Heron Therapeutics' score of 0.69 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, indicating a potential upside of 753.82%. Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 452.49%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eyepoint Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Eyepoint Pharmaceuticals. Heron Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.27	-$231.96M	-$3.74	N/A
Heron Therapeutics	$154.90M	0.44	-$20.19M	-$0.19	N/A

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Palisade Bio?

Heron Therapeutics (NASDAQ:HRTX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Heron Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Heron Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 452.49%. Palisade Bio has a consensus price target of $9.29, indicating a potential upside of 527.41%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Palisade Bio had 6 more articles in the media than Heron Therapeutics. MarketBeat recorded 10 mentions for Palisade Bio and 4 mentions for Heron Therapeutics. Palisade Bio's average media sentiment score of 0.82 beat Heron Therapeutics' score of 0.69 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Palisade Bio's return on equity of -33.47% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Palisade Bio	N/A	-33.47%	-31.79%

Palisade Bio has lower revenue, but higher earnings than Heron Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.44	-$20.19M	-$0.19	N/A
Palisade Bio	$250K	1,031.68	-$16.78M	-$0.48	N/A

Summary

Palisade Bio beats Heron Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 9 mentions for Vanda Pharmaceuticals and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat Vanda Pharmaceuticals' score of 0.48 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics has a net margin of -22.52% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Vanda Pharmaceuticals presently has a consensus price target of $13.08, suggesting a potential upside of 210.03%. Heron Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 452.49%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vanda Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

Heron Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Heron Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.18	-$220.47M	-$4.63	N/A
Heron Therapeutics	$154.90M	0.44	-$20.19M	-$0.19	N/A

Summary

Vanda Pharmaceuticals beats Heron Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to BioAge Labs?

Heron Therapeutics (NASDAQ:HRTX) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

80.0% of Heron Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 17.5% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Heron Therapeutics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.44	-$20.19M	-$0.19	N/A
BioAge Labs	$10.36M	24.02	-$80.61M	-$2.38	N/A

Heron Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 452.49%. BioAge Labs has a consensus price target of $33.00, indicating a potential upside of 508.86%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts plainly believe BioAge Labs is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAge Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, BioAge Labs had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 9 mentions for BioAge Labs and 4 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.69 beat BioAge Labs' score of 0.68 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics has a net margin of -22.52% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
BioAge Labs	-912.26%	-28.99%	-27.09%

Heron Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Heron Therapeutics beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$74.16M	$12.15B	$7.19B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.60%
P/E Ratio	-1.91	678.58	221.68	20.80
Price / Sales	0.44	787.27	546.08	66.79
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	5.17	9.15	10.41	5.92
Net Income	-$20.19M	$2.82B	$3.50B	$380.90M
7 Day Performance	1.06%	-3.78%	-3.49%	-3.90%
1 Month Performance	15.29%	-7.62%	-7.76%	-6.42%
1 Year Performance	-73.19%	-6.11%	0.83%	-6.02%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	2.0389 of 5 stars	$0.36 -7.3%	$2.00 +452.5%	-72.6%	$74.16M	$154.90M	N/A	128	Options Volume Gap Down
ACB Aurora Cannabis	1.0838 of 5 stars	$4.27 -1.8%	N/A	-24.0%	$280.30M	$247.82M	N/A	1,028
EYPT Eyepoint Pharmaceuticals	2.834 of 5 stars	$3.18 -4.4%	$25.70 +709.4%	-77.1%	$272.95M	$2.79M	N/A	214
PALI Palisade Bio	2.5233 of 5 stars	$1.53 -4.1%	$9.29 +508.9%	-20.0%	$265.76M	$250K	N/A	14	Analyst Forecast
VNDA Vanda Pharmaceuticals	3.6737 of 5 stars	$4.40 -3.2%	$13.08 +197.7%	-19.3%	$265.13M	$215.72M	N/A	533	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. ACB, EYPT, PALI, VNDA, and BIOA

How does Heron Therapeutics compare to Aurora Cannabis?

Summary

How does Heron Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Heron Therapeutics compare to Palisade Bio?

Summary

How does Heron Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Heron Therapeutics compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. ACB, EYPT, PALI, VNDA, and BIOA

How does Heron Therapeutics compare to Aurora Cannabis?

Do analysts prefer ACB or HRTX?

Which has preferable valuation and earnings, ACB or HRTX?

Do institutionals and insiders have more ownership in ACB or HRTX?

Is ACB or HRTX more profitable?

Does the media prefer ACB or HRTX?

Which has more risk & volatility, ACB or HRTX?

Summary

How does Heron Therapeutics compare to Eyepoint Pharmaceuticals?

Is EYPT or HRTX more profitable?

Does the media prefer EYPT or HRTX?

Do analysts recommend EYPT or HRTX?

Which has more volatility and risk, EYPT or HRTX?

Which has preferable earnings and valuation, EYPT or HRTX?

Do institutionals & insiders believe in EYPT or HRTX?

Summary

How does Heron Therapeutics compare to Palisade Bio?

Do institutionals and insiders believe in HRTX or PALI?

Which has more volatility & risk, HRTX or PALI?

Do analysts recommend HRTX or PALI?

Does the media refer more to HRTX or PALI?

Is HRTX or PALI more profitable?

Which has higher earnings and valuation, HRTX or PALI?

Summary

How does Heron Therapeutics compare to Vanda Pharmaceuticals?

Do institutionals & insiders hold more shares of VNDA or HRTX?

Does the media prefer VNDA or HRTX?

Is VNDA or HRTX more profitable?

Do analysts recommend VNDA or HRTX?

Which has more volatility and risk, VNDA or HRTX?

Which has higher valuation and earnings, VNDA or HRTX?

Summary

How does Heron Therapeutics compare to BioAge Labs?

Do insiders & institutionals believe in HRTX or BIOA?

Which has better earnings & valuation, HRTX or BIOA?

Do analysts recommend HRTX or BIOA?

Does the media refer more to HRTX or BIOA?

Is HRTX or BIOA more profitable?

Which has more risk & volatility, HRTX or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools